Bicalutamide News and Research

RSS

Heartburn drug Kapidex to be marketed under new name Dexilant

The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant.

4 Mar 2010

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

12 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.

29 Jul 2008

Hormonal nutritional supplements might speed prostate cancer progression

Hormonal components in over-the-counter dietary supplements may promote the progression of prostate cancer and decrease the effectiveness of anti-cancer drugs, researchers at UT Southwestern Medical Center have discovered.

16 Jan 2008

Hormonal components in over-the-counter dietary supplements might promote prostate cancer progression

15 Jan 2008

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases

New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.

26 Sep 2007

New therapies for prostate cancer

A Dutch study suggested treating prostate cancer patients with higher doses of radiotherapy significantly improved patient outcome and treatment over a five-year period.

3 Nov 2005